The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4billion in 2021, at a CAGR of 12.5% during the forecast period. Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies. On the other hand,the requirement of high capital investments and low cost-benefit ratio and the unfavorable regulatory and reimbursement scenario are the major factors hampering the growth of this market.
The consumables segment accounted for the highest growth rate in theimmuno-oncology assaysmarket, by product& service, during the forecast period The immuno-oncology assays market is segmented into consumables, instruments, and software & services based on product & service.In 2020, the consumables segment accounted for the highest growth rate in the immuno-oncology assays market.
The requirement of consumables in large numbers as compared to instruments is the major factor contributing to the growth of this segment.
Research applications segment accounted for the highest CAGR Based on application, the immuno-oncology assays market is segmented into research applications and clinical diagnostics.In 2020, the research applications segmentaccounted for the highest growth rate.
This can be attributed to the rising prominence of biomarker-based drug development.
Asia Pacific: The fastest-growing regionimmuno-oncology assays market The global immuno-oncology assays market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.The Asia Pacific region is projected to register the highest CAGR during the forecast period.
Growth in this region is expected to be centeredon China and Japan. Factors such as the growing number of CROs in the region and the increasing awareness about the early detection of cancer are driving the growth of the immuno-oncology assays market in this region.
The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30% • By Designation: C-level - 27%, D-level - 18%, and Others - 55% • By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report: • Thermo Fisher Scientific, Inc. (US) • F. Hoffmann-La Roche Ltd. (Switzerland) • Agilent Technologies, Inc. (US) • Illumina, Inc. (US) • NanoString Technologies, Inc. (US) • Sartorius AG (Germany) • HTG Molecular Diagnostics, Inc. (US) • QIAGEN N.V. (Netherlands) • Merck Millipore (US) • PerkinElmer, Inc. (US) • Abbott Laboratories, Inc. (US) • Guardant Health, Inc. (US) • bioMérieux SA (France) • Myriad Genetics, Inc. (US) • MESO SCALE DIAGNOSTICS, LLC. (US) • Seegene Inc. (South Korea) • Bio-Rad Laboratories, Inc. (US) • Charles River Laboratories, Inc. (US) • Olink (Sweden) • ASURAGEN, INC. (US) • Invivoscribe, Inc. (US) • Creative Biolabs (US) • ReachBio LLC (US) • NMI Technologietransfer GmbH (Germany)
Research Coverage: This report provides a detailed picture of the global immuno-oncology assays market.It aims at estimating the size and future growth potential of the market across different segments, such as product& service, technology, indication, application, and region.
The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immuno-oncology assays market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
Our reports have been used by over 10K customers, including:
The global interventional oncology market size is projected to reach USD 2.9 billion by 2026 from USD 1.9 billion in 2020, at a CAGR of 6.8%. Factors such as the technological advancements in the market are propelling the growth of the interventional oncology market. Additionally, rising cases of surgeries, investments from both private and...
263 pages •
By Asia Market Information & Development Company
• Apr 2021
China’s demand for Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer...
The oncology information systems market is projected to reach USD 9.5 billion by 2025 from USD 6.7 billion in 2020, at a CAGR of 7.4% during the forecast period. Growth of the market is mainly attributed to the technological advancements; increasing incidences of cancer cases, and growing public and private investments, funding, and grants...
442 pages •
By The Business Research Company
• Nov 2020
Oncology Drugs Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global oncology drugs market. Description: Where is the largest and fastest growing market for the oncology...
The global cold plasma equipment market is expected to reach US$ 308.87 Mn in 2027 from US$ 96.67 Mn in 2019. The market is estimated to grow with a CAGR of 15.6% from 2020-2027. The growth of the cold plasma equipment market is primarily attributed to the factors such as increasing use of cold plasma in medical treatment, increasing...
The cold plasma equipment market in Asia Pacific is anticipated to reach US$ 50.04 million by 2027 from US$ 14.20 million in 2019; it is projected to grow at a CAGR of 17.1% from 2020 to 2027. The growth of the cold plasma equipment market in Asia Pacific is primarily ascribed to the increasing use of cold plasma in therapeutics, growing...
The global cold plasma equipment market is expected to reach US$ 308.14 Mn in 2027 from US$ 96.67 Mn in 2019. The market is estimated to grow with a CAGR of 15.7% from 2020-2027. The growth of the cold plasma equipment market is primarily attributed to the factors such as increasing use of cold plasma in medical treatment, increasing hospital...
Cancer rates could further increase by 50%, to 15 million new cases, by 2020, as per the World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners can prevent as many as one-third of cancers, worldwide. The American Cancer...
The global generic oncology drugs market is expected to reach US$ 36,029.60 Mn in 2027 from US$ 21,200.00 in 2018. The market is estimated to grow with a CAGR of 6.3% from 2019-2027. Factors such as, growing cancer prevalence across the globe, new product launches and benefits offered by generic drugs are boosting the market over the years....
Patient Positioning Systems Market Size, Outlook and Growth Opportunities, 2019- 2025 Global Patient Positioning Systems Market Size, Outlook and Growth Opportunities to 2025: By Product( Tables, Accessories, and Other Patient Positioning Systems), By Applications( Surgery, Dieseases Diagnosis, and Cancer Therapy),...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.